Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Bimagrumab by Eli Lilly and Co for Obesity: Likelihood of Approval
Bimagrumab is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Bimagrumab?
Bimagrumab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity. According...